Clinical trials: Type I Diabetes Mellitus
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate efficacy and safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to…
- Trial name
- Onset® 5 (NCT02825251)
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- 92 sites in United States, Belgium and 7 more
- Volunteers
- 472 people
- Sponsor
- Novo Nordisk A/S
Tumor, Solid
Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
This study will examine whether patients with relapsed/refractory solid tumors harboring evidence of somatic hypermutation (intermediate versus high tumor mutational burden) will exhibit improvement in disease progression-free…
- Trial name
- NCT03911557
- Testing
- Durvalumab and Tremelimumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- John L. Villano, MD, PhD
Type 1 Diabetes
Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes
Clinically, the ability to slow or prevent beta cell demise can prevent or improve the course of type 1 diabetes. The immune-mediated destruction of beta cells that is an apparent major pathological basis for the disease, has led…
- Trial name
- NCT02218619
- Testing
- Tauroursodeoxycholic Acid (TUDCA)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Robin Goland, MD
Diabetes Mellitus, Type 1
Influence of Diabetic Neuropathy on Activation of Brown Adipose Tissue
Influence of diabetic neuropathy on cold induced brown adipose tissue in type 1 diabetic patients.
- Trial name
- DIA-BAT (NCT03695731)
- Testing
- cold induced activation of brown adipose tissue
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- Doctor Giacomo Gastaldi
Congenital Heart Disease, Viremia
Congenital Heart Anomaly Risk in Maternal Enteroviral Infection and Diabetes
Beyond EV-B, there are clinical observations to implicate other viruses in birth defects, including CHD. Since the Rubella epidemic of 1960s', however, viruses have received little attention and certainly no comprehensive study…
- Conditions
- Congenital Heart Disease, Viremia, Virus Diseases, Enterovirus
- Trial name
- CHARMED (NCT04769167)
- Testing
- Stool and Blood Specimen Collection, Follow-up Medical Record Review
- Where
- 2 sites in United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Hypoglycemia, Diabetes Mellitus, Type 1
A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare a needle-free treatment of hypoglycemia with nasal glucagon (study drug) to a marketed glucagon administered by the intramuscular (IM) route, in participants with type 1 diabetes mellitus…
- Trial name
- NCT03339453
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 2 sites in Germany
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver
The purpose of this study is to learn if giving multiple doses of a hormone called glucagon can cause a major decrease in liver glycogen (animal starch).
- Trial name
- NCT01986231
- Testing
- Glucagon
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Legacy Health System
Type 1 Diabetes Mellitus
Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.
Primary Objective: 6 To assess the efficacy of insulin glargine given once daily (QD) on glycosylated hemoglobin (HbA1c) levels over a period of 24 weeks in children with type 1 diabetes mellitus (T1DM) aged at least 6 years to…
- Trial name
- Lantus-P-CN (NCT01223131)
- Testing
- Insulin glargine (HOE901), NPH insulin
- Where
- 10 sites in China
- Volunteers
- 162 people
- Sponsor
- Sanofi
Type 2 Diabetes
A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes
The purpose of this study is to assess safety and tolerability of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes
- Trial name
- MAD (NCT00747175)
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Type 1 Diabetes
Diabetes Distress, Psychological Well-being and Family Hardiness in Parents of Children and Adolescents With T1D
Parents have an important role in child's diabetes management. Many studies show that parental psychological stress and family dynamics are associated with parental diabetes-related distress and treatment outcomes among children…
- Trial name
- NCT02010528
- Where
- Slovenia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
Diabetes, Type 1 Diabetes
Looping Whilst Restricting Carbohydrates
To investigate the efficacy, safety and utility of hybrid closed-loop glucose control during a low carbohydrate vs. iso-energetic balanced diet in individuals with type 1 diabetes.
- Trial name
- LINEAR (NCT03932630)
- Testing
- Low carbohydrate diet, balanced diet
- Where
- Switzerland
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Atherosclerotic Cardiovascular Disease, Childhood Diabetes Mellitus
Atherosclerotic Cardiovascular Risk in Childhood and Teen-age Onset Diabetes
For children and adolescents with diabetes, the pathological process of atherosclerotic cardiovascular disease(ASCVD) can exist in early childhood and progress rapidly to subclinical ASCVD.
- Conditions
- Atherosclerotic Cardiovascular Disease, Childhood Diabetes Mellitus, Juvenile Diabetes
- Trial name
- NCT05294653
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Type 1 Diabetes (T1D), Nutrition Therapy
Meal Frequency and Glycemic Control in Individuals With Type 1 Diabetes
The goal of this clinical trial is to examine the effect of 3 versus 6 daily meals of isocaloric diets on glycemic control and variability in individuals with type 1 diabetes.
- Conditions
- Type 1 Diabetes (T1D), Nutrition Therapy, Glycemic Control for Diabetes Mellitus
- Trial name
- NCT06934707
- Testing
- Three meals a day, Six meals a day
- Where
- Brazil
- Volunteers
- 27 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Diabetes Mellitus, Type 1
A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin Pump
This study is looking at the effect and safety of 3 formulations of the new rapid-acting insulin analogue NNC0471-0119, for the treatment of type 1 diabetes when given by insulin pump.
- Trial name
- NCT05262595
- Testing
- NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D
- Where
- Austria
- Volunteers
- 19 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Liver
Safety Study of Pioglitazone Compared To Glyburide on Liver Function
The purpose of this study is to determine the liver safety of pioglitazone, once daily (QD), versus glyburide taken with metformin and insulin.
- Trial name
- NCT00494312
- Testing
- Pioglitazone, Glyburide
- Volunteers
- 2,120 people
- Sponsor
- Takeda
Type 1 Diabetes
FAMS-T1D Self-Regulation and Social Support for T1D
The goal of this clinical trial is to evaluate how effective the FAMS-T1D intervention is for improving self-regulation (e.g., setting and meeting goals for type 1 diabetes) and social support for meeting those goals for young…
- Trial name
- FAMS-T1D (NCT05820477)
- Testing
- FAMS-T1D, Digital resources for diabetes
- Where
- 2 sites in United States
- Volunteers
- 280 people
- Sponsor
- University of Utah
Diabetes Mellitus, Type 1
ATG-GCSF in New Onset Type 1 Diabetes
This is a three-arm, 1:1:1 randomized, placebo controlled, double- blinded trial in which at least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte colony-stimulating factor (ATG-GCSF), at least 28 subjects…
- Trial name
- ATG-GCSF (NCT02215200)
- Testing
- Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF)
- Where
- 13 sites in United States
- Volunteers
- 89 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Metabolic Impact
INTEGRATED IMPACT ASSESSMENT a Telemedicine Program in the Care of Patients With Diabetes Mellitus Type 1 Intensive Treatment With Multiple Daily Injections.
Prospective study of 6 months of evolution in people with type 1 diabetes with insulin multidose (MDI) and HbA1c> 7%. Patients were evaluated clinical, metabolic and psychological baseline and at 6 months, with a telematic visit…
- Trial name
- NCT02784236
- Testing
- telemedicine
- Where
- Spain
- Volunteers
- 121 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Diabetes Mellitus, Type 1
Relation Between Anthropometric Measurements and Balance in Children With Type 1 Diabetes Relation Between Anthropometric Measurements and Balance in Children With Type 1 Diabetes
Type 1 diabetes mellitus is the most common chronic metabolic disorder in children. Diabetic children who take proper nutrition and good care attain normal growth status.
- Trial name
- NCT05575609
- Testing
- children with Diabetes Mellitus, Type 1
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
Type1diabetes
Observational Study of the Use of DBLG1 System in Real Life
This study will be conducted on human subjects and is observational, prospective and uncontrolled, defined as a category 3 according to the Jardé Law (RIPH3). It is a national and multicentric study.
- Trial name
- SP12 (NCT04749693)
- Testing
- DBLG1 System
- Where
- 20 sites in France
- Volunteers
- 348 people
- Sponsor
- Diabeloop